It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their US ...
Hosted on MSN37m
Wall Street Analysts Thought Merck Stock Had 10% Downside Risk Heading Into Earnings. That Materialized, So What’s Next?Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...
Even those PEPFAR programs operating must limit distribution of preventive medication, according to apparent State Department ...
However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...
New licensing Guidelines issued by the National Institutes of Health at the end of the Biden Administration could harm ...
Yuka Manabe and her team at the Center for Innovative Diagnostics for Infectious Diseases aim to improve global health with ...
Unlike opium, nitazenes and other synthetic opioids can be produced anywhere in the world using precursor chemicals that are often uncontrolled.
Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...
Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while ...
Conduit and Sarborg complete all milestones of Phase I of their AI-driven drug development collaboration, and commence transitioning to Phase II, ...
President Trump spread unfounded claims that the government had paid Politico and other news media outlets for positive ...
Medical equipment maker Mettler-Toledo International forecast annual profit above estimates on Thursday, banking on strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback